Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | NA |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | oesophageal squamous cell carcinoma |
| ICD-0-3 | NA |
| Methods | qRT-PCR, Western blotting etc. |
| Sample | ESCC and matched adjacent normal tissues,ESCC cell lines (EC109, EC9706, KYSE150, KYSE450, and KYSE510) |
| Expression Pattern | down-regulated |
| Function Description | MEG3 expression was significantly downregulated in tumour tissues, and its low expression was associated with large tumour size, lymph node metastasis and advanced clinical stage in ESCC patients. Univariate and multivariate analyses revealed low expression of MEG3 as an independent predictor for disease-free survival and overall survival. Cell experiments showed that MEG3 inhibited ESCC cell proliferation, migration and invasion. Subsequently, miR-4261 was identified and confirmed to be the target of MEG3, and MEG3 functions, at least in part, by targeting miR-4261. Additionally, Dickkopf-2 (DKK2), a Wnt/?-catenin signalling inhibitor, was identified to be a target of miR-4261. MEG3 interacted with miR-4261, derepressed DKK2 and blocked the Wnt/?-catenin signalling, thereby inhibiting tumourigenesis and progression in ESCC. |
| Pubmed ID | 30990378 |
| Year | 2019 |
| Title | Downregulated MEG3 Contributes to Tumour Progression and Poor Prognosis in Oesophagal Squamous Cell Carcinoma by Interacting With miR-4261, Downregulating DKK2 and Activating the Wnt/?-catenin Signalling |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for oesophageal squamous cell carcinoma | OMIM COSMIC |